Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

<p>Design of dose-escalation phase. CRM, continuous reassessment model; Q3W, once every 3 weeks; 3Q4W, 3 weekly doses every 4 weeks</p>

שמור ב:
מידע ביבליוגרפי
מחבר ראשי: Kristoffer Staal Rohrberg (15009138) (author)
מחברים אחרים: Juanita S. Lopez (22687839) (author), Mohammed M. Milhem (15352499) (author), Christian U. Blank (14850778) (author), Irene Reijers (22687842) (author), Fiona Thistlethwaite (22687845) (author), Ruth Plummer (15028641) (author), Sarina A. Piha-Paul (15294428) (author), Pasi A. Jänne (14954872) (author), Elaine Shum (14955138) (author), Heather M. Shaw (22687848) (author), Philip R. Debruyne (20432881) (author), Cristopher Lao (22687851) (author), Jean-Francois Baurain (15031089) (author), Jennifer H. Choe (15052775) (author), Eelke Gort (17740951) (author), Yujie Zhao (22687854) (author), Guy Jerusalem (15017648) (author), Patrick Schöffski (15013461) (author), Andrew William Chen (22687857) (author), Eric A. Cohen (15017996) (author), Walter C. Mankowski (22687860) (author), Leonid Roshkovan (22687863) (author), Sharyn I. Katz (22687866) (author), Despina Kontos (15018005) (author), Lauren K. Brady (22687869) (author), Mohammed Qutaish (22687872) (author), Patricia Garrido Castro (22687875) (author), Nora Pencheva (22687878) (author), Gaurav Bajaj (22687881) (author), Yali Fu (22687884) (author), Kristian Windfeld (22687887) (author), Panagiota Reiter (22687890) (author), Maria Jure-Kunkel (15117740) (author), Brandon W. Higgs (15035279) (author), Katayoun I. Amiri (22687893) (author), Tahamtan Ahmadi (22687896) (author), Ulf Forssmann (22687899) (author), Suresh S. Ramalingam (14951413) (author), Ignace Vergote (15027870) (author)
יצא לאור: 2025
נושאים:
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
_version_ 1849927621935104000
author Kristoffer Staal Rohrberg (15009138)
author2 Juanita S. Lopez (22687839)
Mohammed M. Milhem (15352499)
Christian U. Blank (14850778)
Irene Reijers (22687842)
Fiona Thistlethwaite (22687845)
Ruth Plummer (15028641)
Sarina A. Piha-Paul (15294428)
Pasi A. Jänne (14954872)
Elaine Shum (14955138)
Heather M. Shaw (22687848)
Philip R. Debruyne (20432881)
Cristopher Lao (22687851)
Jean-Francois Baurain (15031089)
Jennifer H. Choe (15052775)
Eelke Gort (17740951)
Yujie Zhao (22687854)
Guy Jerusalem (15017648)
Patrick Schöffski (15013461)
Andrew William Chen (22687857)
Eric A. Cohen (15017996)
Walter C. Mankowski (22687860)
Leonid Roshkovan (22687863)
Sharyn I. Katz (22687866)
Despina Kontos (15018005)
Lauren K. Brady (22687869)
Mohammed Qutaish (22687872)
Patricia Garrido Castro (22687875)
Nora Pencheva (22687878)
Gaurav Bajaj (22687881)
Yali Fu (22687884)
Kristian Windfeld (22687887)
Panagiota Reiter (22687890)
Maria Jure-Kunkel (15117740)
Brandon W. Higgs (15035279)
Katayoun I. Amiri (22687893)
Tahamtan Ahmadi (22687896)
Ulf Forssmann (22687899)
Suresh S. Ramalingam (14951413)
Ignace Vergote (15027870)
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author_facet Kristoffer Staal Rohrberg (15009138)
Juanita S. Lopez (22687839)
Mohammed M. Milhem (15352499)
Christian U. Blank (14850778)
Irene Reijers (22687842)
Fiona Thistlethwaite (22687845)
Ruth Plummer (15028641)
Sarina A. Piha-Paul (15294428)
Pasi A. Jänne (14954872)
Elaine Shum (14955138)
Heather M. Shaw (22687848)
Philip R. Debruyne (20432881)
Cristopher Lao (22687851)
Jean-Francois Baurain (15031089)
Jennifer H. Choe (15052775)
Eelke Gort (17740951)
Yujie Zhao (22687854)
Guy Jerusalem (15017648)
Patrick Schöffski (15013461)
Andrew William Chen (22687857)
Eric A. Cohen (15017996)
Walter C. Mankowski (22687860)
Leonid Roshkovan (22687863)
Sharyn I. Katz (22687866)
Despina Kontos (15018005)
Lauren K. Brady (22687869)
Mohammed Qutaish (22687872)
Patricia Garrido Castro (22687875)
Nora Pencheva (22687878)
Gaurav Bajaj (22687881)
Yali Fu (22687884)
Kristian Windfeld (22687887)
Panagiota Reiter (22687890)
Maria Jure-Kunkel (15117740)
Brandon W. Higgs (15035279)
Katayoun I. Amiri (22687893)
Tahamtan Ahmadi (22687896)
Ulf Forssmann (22687899)
Suresh S. Ramalingam (14951413)
Ignace Vergote (15027870)
author_role author
dc.creator.none.fl_str_mv Kristoffer Staal Rohrberg (15009138)
Juanita S. Lopez (22687839)
Mohammed M. Milhem (15352499)
Christian U. Blank (14850778)
Irene Reijers (22687842)
Fiona Thistlethwaite (22687845)
Ruth Plummer (15028641)
Sarina A. Piha-Paul (15294428)
Pasi A. Jänne (14954872)
Elaine Shum (14955138)
Heather M. Shaw (22687848)
Philip R. Debruyne (20432881)
Cristopher Lao (22687851)
Jean-Francois Baurain (15031089)
Jennifer H. Choe (15052775)
Eelke Gort (17740951)
Yujie Zhao (22687854)
Guy Jerusalem (15017648)
Patrick Schöffski (15013461)
Andrew William Chen (22687857)
Eric A. Cohen (15017996)
Walter C. Mankowski (22687860)
Leonid Roshkovan (22687863)
Sharyn I. Katz (22687866)
Despina Kontos (15018005)
Lauren K. Brady (22687869)
Mohammed Qutaish (22687872)
Patricia Garrido Castro (22687875)
Nora Pencheva (22687878)
Gaurav Bajaj (22687881)
Yali Fu (22687884)
Kristian Windfeld (22687887)
Panagiota Reiter (22687890)
Maria Jure-Kunkel (15117740)
Brandon W. Higgs (15035279)
Katayoun I. Amiri (22687893)
Tahamtan Ahmadi (22687896)
Ulf Forssmann (22687899)
Suresh S. Ramalingam (14951413)
Ignace Vergote (15027870)
dc.date.none.fl_str_mv 2025-11-26T07:40:29Z
dc.identifier.none.fl_str_mv 10.1158/2767-9764.30719283
dc.relation.none.fl_str_mv https://figshare.com/articles/figure/Figure_S1_from_Phase_I_II_Study_of_AXL-Specific_Antibody_Drug_Conjugate_Enapotamab_Vedotin_in_Patients_with_Advanced_Solid_Tumors/30719283
dc.rights.none.fl_str_mv CC BY
info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv Cancer
Immuno-oncology
Clinical Research and Trials
Clinical Trial Results
Immunology
Antibodies/immunoconjugates
Lung Cancer
Melanoma
Ovarian Cancer
Sarcomas
dc.title.none.fl_str_mv Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
dc.type.none.fl_str_mv Image
Figure
info:eu-repo/semantics/publishedVersion
image
description <p>Design of dose-escalation phase. CRM, continuous reassessment model; Q3W, once every 3 weeks; 3Q4W, 3 weekly doses every 4 weeks</p>
eu_rights_str_mv openAccess
id Manara_bb88394833eea6862af830673320cb35
identifier_str_mv 10.1158/2767-9764.30719283
network_acronym_str Manara
network_name_str ManaraRepo
oai_identifier_str oai:figshare.com:article/30719283
publishDate 2025
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv CC BY
spelling Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid TumorsKristoffer Staal Rohrberg (15009138)Juanita S. Lopez (22687839)Mohammed M. Milhem (15352499)Christian U. Blank (14850778)Irene Reijers (22687842)Fiona Thistlethwaite (22687845)Ruth Plummer (15028641)Sarina A. Piha-Paul (15294428)Pasi A. Jänne (14954872)Elaine Shum (14955138)Heather M. Shaw (22687848)Philip R. Debruyne (20432881)Cristopher Lao (22687851)Jean-Francois Baurain (15031089)Jennifer H. Choe (15052775)Eelke Gort (17740951)Yujie Zhao (22687854)Guy Jerusalem (15017648)Patrick Schöffski (15013461)Andrew William Chen (22687857)Eric A. Cohen (15017996)Walter C. Mankowski (22687860)Leonid Roshkovan (22687863)Sharyn I. Katz (22687866)Despina Kontos (15018005)Lauren K. Brady (22687869)Mohammed Qutaish (22687872)Patricia Garrido Castro (22687875)Nora Pencheva (22687878)Gaurav Bajaj (22687881)Yali Fu (22687884)Kristian Windfeld (22687887)Panagiota Reiter (22687890)Maria Jure-Kunkel (15117740)Brandon W. Higgs (15035279)Katayoun I. Amiri (22687893)Tahamtan Ahmadi (22687896)Ulf Forssmann (22687899)Suresh S. Ramalingam (14951413)Ignace Vergote (15027870)CancerImmuno-oncologyClinical Research and TrialsClinical Trial ResultsImmunologyAntibodies/immunoconjugatesLung CancerMelanomaOvarian CancerSarcomas<p>Design of dose-escalation phase. CRM, continuous reassessment model; Q3W, once every 3 weeks; 3Q4W, 3 weekly doses every 4 weeks</p>2025-11-26T07:40:29ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/2767-9764.30719283https://figshare.com/articles/figure/Figure_S1_from_Phase_I_II_Study_of_AXL-Specific_Antibody_Drug_Conjugate_Enapotamab_Vedotin_in_Patients_with_Advanced_Solid_Tumors/30719283CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307192832025-11-26T07:40:29Z
spellingShingle Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Kristoffer Staal Rohrberg (15009138)
Cancer
Immuno-oncology
Clinical Research and Trials
Clinical Trial Results
Immunology
Antibodies/immunoconjugates
Lung Cancer
Melanoma
Ovarian Cancer
Sarcomas
status_str publishedVersion
title Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
title_full Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
title_fullStr Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
title_full_unstemmed Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
title_short Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
title_sort Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
topic Cancer
Immuno-oncology
Clinical Research and Trials
Clinical Trial Results
Immunology
Antibodies/immunoconjugates
Lung Cancer
Melanoma
Ovarian Cancer
Sarcomas